Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate

PLoS Computational Biology

Volumn 11, Issue 1, 2015, Pages

  Salvat, Regina S ^a   Parker, Andrew S ^b   Choi, Yoonjoo ^b   Bailey Kellogg, Chris ^b   Griswold, Karl E ^a,c  

^a DARTMOUTH COLLEGE   (United States)

^b Dartmouth College   (United States)

^c Program in Molecular and Cellular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCE; EPITOPES; PARETO PRINCIPLE; T-CELLS;

BIOTHERAPEUTICS; CLINICAL APPLICATION; DESIGN SPACES; HIGH-LEVEL FUNCTIONS; IMMUNOGENICITY; OPTIMAL DESIGN SPACE; PARETO FRONTIERS; PARETO-OPTIMAL DESIGN; PERFORMANCE; T-CELL EPITOPES;

PROTEINS;

BETA LACTAMASE; P99 BETA LACTAMASE; UNCLASSIFIED DRUG; EPITOPE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; BIOLOGICAL THERAPY; COMPUTER MODEL; DEIMMUNIZATION; GENE DELETION; IMMUNIZATION; IMMUNOGENICITY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PREDICTION; PROCESS DESIGN; PROCESS OPTIMIZATION; PROTEIN ENGINEERING; BIOLOGY; CHEMISTRY; COMPUTER SIMULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROCEDURES; STATISTICAL MODEL;

ALGORITHMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; EPITOPES, T-LYMPHOCYTE; HUMANS; MODELS, STATISTICAL; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84922215375     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003988     Document Type: Article

References (47)

1. Biologic drugs set to top 2012 sales. Nat Med 18: 636–636.
2. Aggarwal S, (2014) What's fueling the biotech engine - 2012 to 2013. Nat Biotech 32: 32–39.
3. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ, (2010) Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1: 314–322.
4. Barbosa MD, (2011) Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 16: 345–353.
5. De Groot AS, Scott DW, (2007) Immunogenicity of protein therapeutics. Trends in Immunology 28: 482–490.
6. Schellekens H, (2007) Immunogenicity of protein therapeutics, or how to make antibodies without T-cells. Inflammation Research 56: S351–S352.
7. Schellekens H, (2010) The Immunogenicity of Therapeutic Proteins. Discovery Medicine 49: 560–564.
8. Trombetta ES, Mellman I, (2005) Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23: 975–1028.
9. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, et al. (2005) A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4: 1791–1800.
10. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC, (2009) Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin. Journal of Immunotherapy 32: 574–584 510.1097/CJI.1090b1013e3181a6981c.
11. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, et al. (2012) Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proceedings of the National Academy of Sciences 109: E3597–E3603.
12. Tangri S, Mothe BR, Eisenbraun J, Sidney J, Southwood S, et al. (2005) Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity. J Immunol 174: 3187–3196.
13. Warmerdam PAM, Plaisance S, Vanderlick K, Vandervoort P, Brepoels K, et al. (2002) Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thrombosis and Haemostasis 87: 666–673.
14. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, et al. (2004) Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope. The Journal of Immunology 172: 6658–6665.
15. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, et al. (2005) Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57: 304–314.
16. Guan P, Doytchinova IA, Zygouri C, Flower DR, (2003) MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. Appl Bioinformatics 2: 63–66.
17. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S, (2010) NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6: 9.
18. Nielsen M, Lundegaard C, Lund O, (2007) Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8: 238.
19. Perry LC, Jones TD, Baker MP, (2008) New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 9: 385–396.
20. Singh H, Raghava GP, (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17: 1236–1237.
21. Wan J, Liu W, Xu Q, Ren Y, Flower DR, et al. (2006) SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics 7: 463.
22. Wang P, Sidney J, Dow C, Mothe B, Sette A, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4: e1000048.
23. De Groot AS, Moise L, (2007) Prediction of immunogenicity for therapeutic proteins: State of the art. Current Opinion in Drug Discovery & Development 10: 332–340.
24. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, et al. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A 108: 1272–1277.
25. Osipovitch DC, Parker AS, Makokha CD, Desrosiers J, Kett WC, et al. (2012) Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel 25: 613–623.
26. De Groot AS, Knopp PM, Martin W, (2005) De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel) 122: 171–194.
27. Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C, (2010) Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 11: 180.
28. Parker AS, Griswold KE, Bailey-Kellogg C, (2011) Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol 9: 207–229.
29. Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C, (2013) Structure-guided deimmunization of therapeutic proteins. J Comput Biol 20: 152–165.
30. Choi Y, Griswold Ke, Bailey-Kellogg C Structure-based redesign of proteins for minimal T-cell epitope content.
31. Salvat RS, Parker AS, Guilliams A, Choi Y, Bailey-Kellogg C, et al. (2014) Computationally Driven Deletion of Broadly Distributed T cell Epitopes in a Biotherapeutic Candidate. Cellular and Molecular Life Sciences: 1–12.
32. He L, Friedman AM, Bailey-Kellogg C, (2012) A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments. Proteins: Structure, Function, and Bioinformatics 80: 790–806.
33. Salvat RS, Moise L, C B-K, Griswold KE, (2014) A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes. J Vis Exp 85: e51308.
34. Nielsen M, Lund O (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10.
35. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, et al. (2006) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. The Journal of Experimental Medicine 203: 961–971.
36. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotech 17: 555–561.
37. Moise L, Song C, Martin WD, Tassone R, De Groot AS, et al. (2012) Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clinical Immunology 142: 320–331.
38. Moise L, McMurry JA, Buus S, Frey S, Martin WD, et al. (2009) In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 27: 6471–6479.
39. De Groot AS, Martin W, (2009) Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clinical Immunology 131: 189–201.
40. Sidney J, del Guercio M-F, Southwood S, Sette A, (2002) The HLA Molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 Share an Extensive Overlap in Peptide Binding Specificity. The Journal of Immunology 169: 5098–5108.
41. Hill JA, Wang DQ, Jevnikar AM, Cairns E, Bell DA, (2003) The relationship between predicted peptide-MHC class II affinity and T-cell activation in a HLA-DR beta 1*0401 transgenic mouse model. Arthritis Research & Therapy 5: R40–R48.
42. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. Journal of Immunology 160: 3363–3373.
43. Warmerdam PA, Plaisance S, Vanderlick K, Vandervoort P, Brepoels K, et al. (2002) Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost 87: 666–673.
44. Onda M, (2009) Reducing the Immunogenicity of Protein Therapeutics. Current Drug Targets 10: 131–139.
45. McCaldon P, Argos P, (1988) Oligopeptide Biases in Protein Sequences and Their Use in Predicting Protein Coding Regions in Nucleotide-Sequences. Proteins-Structure Function and Genetics 4: 99–122.
46. De Groot AS, Martin W, (2009) Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 131: 189–201.
47. Paul S, Kolla RV, Sidney J, Weiskopf D, Fleri W, et al. (2013) Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource. Clinical & Developmental Immunology 2013: 467852.